ArticleJCO precision oncology2025
Transgender and Gender-Diverse Patient Perspectives on Hereditary Breast Cancer Risk Assessment in Gender-Affirming Top Surgeries.
Article in JCO precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- LGBTQ+ individuals' experiences of initial identity disclosure in primary healthcare services: a qualitative scoping review.International journal of nursing studies advances · 2026Review
- Healthcare professional perspectives on hereditary breast cancer risk assessment prior to gender-affirming mastectomy.Breast cancer research and treatment · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTransgender and gender-diverse (TGD) people have increased cancer morbidity and mortality relative to cisgender individuals. Existing breast cancer prevention guidelines fail to adequately address gender-affirming care implications, especially in the context of gender-affirming mastectomies (top surgery). Evaluation of familial and germline genetic risk before top surgery is recommended by some transgender health guidelines. This evaluation can facilitate shared surgical decision making regarding breast tissue resection extent. In this study, we use in-depth interviews with TGD people planning or having recently undergone top surgery. We aimed to understand barriers and facilitators to pre- and post-top surgery breast cancer risk assessment and screening, and the perceived utility and acceptability of presurgical genetic evaluation.
methodsWe conducted qualitative community-engaged research through interviews with 16 TGD adults who had or were considering top surgery. Through a social constructivist lens, we used reflexive thematic analysis to generate themes.
resultsWe conceptualized six key themes: (1) post-top surgery cancer screening uncertainty, (2) lack of provider knowledge hindering appropriate care, (3) the experience of breast health spaces as heavily feminized, (4) the balance of aesthetic goals with cancer risk reduction, (5) increased comfort with postsurgical screening because of reduced dysphoria and greater body confidence, and (6) the desire for cancer genetics integration with top surgery care navigation.
conclusionFrom these themes, we derived actionable guidance to address breast cancer health equity in this population. Enhancing patient education, increasing provider awareness, and developing inclusive clinical practice guidelines are crucial steps in effectively addressing breast cancer risk in individuals receiving surgery. It is vital to degender health spaces to promote inclusion and accessibility of breast cancer prevention. Integrating genetics professionals and cancer risk assessment into transgender health clinics and the top surgery process is paramount for delivering personalized care and facilitating informed surgical decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.